Ifetroban
Unknown / undisclosed
Evidence outlook
Systemic Sclerosis: topline reported 2026-10-23
The sponsor reported topline results on 2026-10-23 (Phase 2 ASSIST-SSc pilot of ifetroban reports top-line safety results). The announcement is listed under Regulatory events.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02682511 NCT02682511 · Systemic Sclerosis Registry: NCT02682511 | 2 | Incidence of adverse events (AEs) and Serious AEs (SAEs) (56 weeks) 2026-03 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (10)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Competitive landscape
This drug's own stage for Systemic Sclerosis: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Ifetroban: this drug | Phase 2 | — | Thromboxane A2 receptor (TP receptor) | not yet graded | No reviewed efficacy summary in this indication | |
| Nintedanib (Ofev) | Approved | Small molecule | Triple angiokinase inhibitor (VEGFR/FGFR/PDGFR) | not yet graded | No reviewed efficacy summary in this indication | |
| Anifrolumab | Phase 3 | Monoclonal antibody | Type I interferon receptor subunit 1 (IFNAR1) | not yet graded | No reviewed efficacy summary in this indication | |
| Bosentan (Tracleer) | Phase 3 | Small molecule | Endothelin receptor (ETA/ETB, dual) | not yet graded | No reviewed efficacy summary in this indication | |
| Divozilimab (Ivlizi) | Phase 3 | Monoclonal antibody | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Nerandomilast (Jascayd) | Phase 3 | Small molecule | PDE4B | not yet graded | No reviewed efficacy summary in this indication | |
| Treprostinil (Yutrepia, Liquidia) | Phase 2 | Small molecule | IP receptor (prostacyclin pathway) | not yet graded | No reviewed efficacy summary in this indication | |
| Tulisokibart | Phase 2 | Monoclonal antibody | TL1A | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Ifetroban to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
January 2028 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent